Ophthalmic Challenges in 2022
Ophthalmology times asked Farhad Hafezi about what he thinks are the Ophthalmic Challenges in 2022
Mark Hillen
April 26, 2022
Ophthalmology times asked Farhad Hafezi about what he thinks are the Ophthalmic Challenges in 2022
The ELZA Institute had a strong presence at the 82nd SBAO annual congress in Bern. Prof. Kaweh Mansouri, Dr. Emilio Torres-Netto and Ms. Julia Schinzel all
Shaopei Wang et al. wanted to know who are the current “big hitters” in corneal cross-linking (CXL) research, so they performed and published a literature
Professor Farhad Hafezi from the ELZA Institute has prepared a presentation that provides a comprehensive overview of how oxygen concentration is at the center of all these decisions. CXL and oxygen is at the center of everything to do with the UV-riboflavin cross-linking reaction
Today, a landmark PACK-CXL trial was published that shows that PACK-CXL is an effective corneal infection therapy.
Prof. Hafezi, Medical Director of the ELZA Institute in Dietikon, Zurich, Switzerland, co-authored a recently published paper that indicated that obese adults have a lower
TouchOphthalmology interviewed Prof. Farhad Hafezi on why it’s taken until now to have an effective epi-on CXL solution.
The Tear Film & Ocular Surface Society (TFOS) is a non-profit organization, created with the aim of advancing the field of tear film and ocular
“PACK-CXL is safe for use in bacterial keratitis cases. It also seems to add value in reducing healing time and improving final visual acuity while reducing the need for tectonic keratoplasty” noted the study authors.
Insieme21, an association for people with trisomy 21, their parents, carers, and relatives in German-speaking Switzerland, recently featured the ELZA Institute in the 2021 edition
